<DOC>
	<DOCNO>NCT02821559</DOCNO>
	<brief_summary>Raltitrexed potent thymidylate synthase ( TS ) inhibitor . Conversely 5-fluorouracil ( 5FU ) , raltitrexed administer safely patient cardiovascular disease , well patient dihydropyrimidine dehydrogenase deficit . Since raltitrexed administer 15-minutes infusion , complication relate continuous infusion avoid , become potential good candidate locoregional treatment hepatic intra-arterial intra-peritoneal infusion . Despite potential benefit 5FU , clinical trial fail temptation replace 5FU colorectal cancer patient , mainly due raltitrexed toxicity 3mg/m2 every 3 week . Oxaliplatin demonstrate synergic effect combine TS inhibitor , association raltitrexed evaluate 130mg/m2 oxaliplatin 3mg/m2 raltitrexed , every 3 week . Actually , one first-line standard regimens metastatic colorectal cancer patient biweekly FOLFOX ( 85mg/m2 oxaliplatin , infusional 5FU ) plus bevacizumab regimen , since significant progression-free survival ( PFS ) benefit observed FOLFOX plus placebo . Biweekly administration raltitrexed 2mg/m2 demonstrate favorable toxicity profile even patient age &gt; 65 year . Besides , association raltitrexed , oxaliplatin bevacizumab seem safe . Then , investigator decide perform randomize pharmacokinetic comparative study biweekly TOMOX ( raltitrexed 2 mg/m2 oxaliplatin 85mg/m2 ) triweekly TOMOX ( raltitrexed 3 mg/m2 oxaliplatin 130mg/m2 ) regimens metastatic colorectal cancer patient , `` ping-pong '' crossover strategy reduce intra-individual variability . Bevacizumab allow dose 5mg/kg 7.5mg/kg , biweekly triweekly schedule , respectively . The secondary end-points , objective response rate evaluate RECIST 1.1 criterion , PFS , overall survival ( OS ) , toxicity , comparison toxicity two arm first 2 cycle .</brief_summary>
	<brief_title>Biweekly Versus Triweekly Raltitrexed With Oxaliplatin ( With Without Bevacizumab ) First-line Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>performance status ( ECOGPS ) 0 1 patient histologically proven colorectal cancer distant metastases measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 life expectancy &gt; 12 month sign write informed consent prior chemotherapy metastatic stage presence brain meningeal metastases malignancy past 5 year exception adequately treat carcinoma situ cervix squamous basal cell carcinoma skin preexist peripheral neuropathy know hypersensitivity component study treatment psychiatric condition compromise understanding information conduct study pregnancy , breastfeed absence adequate contraception fertile patient patient guardianship , curator protection justice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>raltitrexed</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>biweekly</keyword>
	<keyword>triweekly</keyword>
</DOC>